NEX-I is a next-gen biotech company that can present a new paradigm in immunotherapy for cancers. Its world-class experts have established a platform technology to introduce a new target, ONCOKINE™, that induces cancer cells to become refractory to the current treatment. This proprietary platform enables NEX-I to identify the mechanism of refractory cells and discover inhibitory actions on ONCOKINE™. NEX-I is here to suggest a newly standardized solution by linking ONCOKINE™ suppression to inhibition of cancer cell growth and metastasis.